Palisade Bio PALI 深 滬
等待開盤 11-04 09:30:00 美东时间
1.21
+0.090
+8.04%
華盛通- 最 高1.24
- 今 開1.14
- 成交量 153.94万股
- 最 低 1.13
- 昨 收 1.12
- 總市值 2.11亿
- 52周最高 2.855
- 市盈率 靜 --
- 換手率 0.88%
- 52周最低 1.08
- 委 比 -50.80%
- 總股本 1.74亿
- 歷史最高 18405.00
- 量 比 0.52
- 振 幅 9.82%
- 歷史最低 0.53
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability 29 of 30 planned U.S. sites already activated Global expansion progressing toward ~115 total sites, with CT...
10-28 20:34
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio has initiated its Phase 2b ASCENTRA-UC trial for PALI-2108, a once-daily oral PDE4 inhibitor prodrug targeting ulcerative colitis. The trial aims to evaluate the drug's efficacy and safety in 204 patients across two dose levels. PALI-2108 is designed for targeted activation in the terminal ileum and colon, potentially improving tolerability compared to existing PDE4 inhibitors. The company has activated 29 of 30 U.S. sites and is exp...
10-28 12:32
美股大行评级 | 潜在涨幅91.5%！巴克莱上调Vertical Aerospace评级至"标配"，目标价下调至1美元
今日重点评级关注：巴克莱：上调Vertical Aerospace评级至"标配"，目标价从2美元降至1美元；巴克莱：维持Bitdeer Technologies"超配"评级，目标价从15美元升至17美元
10-12 14:52
Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6
Raymond James analyst Thomas Deal initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $6.
10-09 19:11
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year
Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Inves...
09-22 20:36
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Palisade Bio, Inc. announced that its CEO, JD Finley, and CMO, Mitchell Jones, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026, at 1:00 PM ET. The presentation will cover updates on the company's PALI-2108 clinical program, including progress in ulcerative colitis and Crohn’s disease, and upcoming milestones. A live webcast and replay will be available on the company’s website. Management will also ...
09-21 13:00
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of ServiceTitan Inc (NASDAQ:TTAN) fell sharply in pre-market trading after the company reported second-quarter financial results and issued third-quarter sales guidance with its midpoint below e...
09-09 20:02
Palisade Bio to Participate in Upcoming Investor Conferences
Palisade Bio, a clinical-stage biopharmaceutical company, announced its management will participate in three healthcare investor conferences in September 2026: the Wells Fargo Healthcare Conference in Boston, the Morgan Stanley Global Healthcare Conference in New York, and the H.C. Wainwright Global Investment Conference in New York. The company will host fireside chats and investor meetings, with live webcasts available on its website. Palisade ...
09-03 13:00
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same period last year. The company reported $500.000 thousand in sales this quarter.
08-11 05:05
